Home » Topics » Regulatory » NMPA

NMPA
RSS

Calcium channel blocker for hypertension clear to enter clinical testing in China

March 14, 2012

Antisense Therapeutics to form joint venture for development of ATL-1102

Feb. 29, 2012

Ready-to-use oral therapy approved in China for oral mucositis in patients with cancer

Feb. 28, 2012

Milestone developments for Novartis' Lucentis and Galvus in China

Jan. 19, 2012

F-647 approved in China

Sep. 22, 2011

First iguratimod product approved in China

Aug. 26, 2011

High-dose EPIAO approved in China to treat chemotherapy-associated anemia

July 14, 2011

Chinese health authorities approve Novo Nordisk's Victoza for type 2 diabetes

March 16, 2011

Hutchison MediPharma begins phase I trial of fruquintinib in China

Feb. 2, 2011

TPIAO approved in China for idiopathic thrombocytopenic purpura

Jan. 26, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...